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The cornea is the outermost, clear layer of the eye.  It is also the most important refractive structure of the
eye, which is critical to vision.  The cornea is very vulnerable to injury or infection and corneal injury and
infection often result in corneal scarring and angiogenesis (i.e. the formation of blood vessels).  Corneal
scarring damages vision and can cause blindness.  Our research is aimed at determining the mechanisms
by which Suberanilohydroxamic Acid (SAHA), modulates key molecular regulators of corneal wound
healing, specifically TGF-?1 and also investigating the safety and efficacy of topical SAHA as an anti-
fibrotic therapy in dogs.  Common dog models used to study corneal wounds do not result in significant
corneal scarring, which is what we are specifically interested in trying to treat.  Other research has shown
that the best animal models utilize a corneal alkali burn to create a wound which then heals with scarring
and blood vessel formation.  Therefore, we also aimed to develop a novel model of corneal scarring in dogs
using the alkali burn. We found that SAHA inhibits components of TGF-?1 intracellular signaling pathway
and modulates activity of extracellular matrix proteinases in cell cultures (e.g. in vitro) and that the alkali
burn caused notable corneal scarring in dogs (e.g. in vivo); however, SAHA did not significantly reduce
fibrosis in this model. 
